ALNY— AI Stock Forecast & Price Targets
Published 7/13/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live ALNY price forecast →
ALNY at ~$298 sits in a post-spike consolidation after a rival ATTR-CM trial failure (AZN/IONS Wainua) opened up competitive whitespace, but the stock has already given back most of the July 9 spike from $360 back to the $281-298 range. Fundamentals show explosive top-line growth (Q1'26 revenue +51% YoY to $1.17B, TTR franchise dominant) and swing to profitability, but valuation (75x trailing P/E, 22x fwd) prices in flawless execution into the July 30 earnings print. Accumulate on weakness ahead of a binary earnings catalyst in ~17 days; do not size aggressively into the print.
1-4 week view is dominated by the July 30 earnings print (~17 days). Stance: do NOT add aggressively into the print — this is a binary event with a history of large post-earnings gaps (EPS surprise +73%, sales surprise +4.6%). Pre-earnings I would hold a starter position sized for a full ATR (~$15) drawdown. Buy zone: $278-288 (retest of Jul 11 low $281.83 and $273 52-wk low). Trim/skip if we spike back to $325-335 pre-print without new data. Invalidation: daily close below $273 breaks 52-week support and forces a re-underwriting. Earnings is the key catalyst AND the key invalidation event — a miss on TTR revenue guidance is the biggest single risk.
1-6 month view: constructive. The Wainua failure structurally improves AMVUTTRA's competitive position in ATTR-CM, and 2026 guidance ($4.9-5.3B combined product rev, $4.4-4.7B TTR) has upside if the field of competition is thinner. Expected return range from current $298: -8% to +25% (base $335, bull $385) over 6 months, hinging on Q2 print and TRITON-CM/TRITON-PN Phase 3 enrollment readouts. What would change my mind: (1) Q2 earnings miss or guide-down, (2) TTR revenue growth deceleration below +30% YoY, (3) FDA/EMA safety signal on AMVUTTRA, (4) daily close below $273. Analyst target consensus $446 is aspirational but reflects the recovering narrative.
1-3 year view: ALNY is a leveraged bet on the RNAi platform monetizing across TTR, CV/metabolic (zilebesiran, ALN-APOC3), and neuro (mivelsiran) indications, with the Alnylam 2030 strategy targeting TTR global leadership. Structural drivers: platform validation via Roche/Regeneron/Sanofi/Novartis partnerships, pipeline breadth (multiple Phase 3 assets), and durable 80%+ gross margins. Biggest structural risks: (1) valuation compression if RNAi platform faces a safety issue in any high-visibility indication, (2) IRA/pricing pressure on rare-disease drugs, (3) capital allocation drag from the $2B Inceptive AI deal if returns are slow to materialize, (4) competitive erosion in TTR from CRISPR/gene therapy modalities (Intellia, etc.). Long-term price potential $450-550 if 2028+ TTR franchise clears $6B.
Revenue trajectory is the strongest part of the story: Q1'26 revenue of $1.167B is a step-change vs. the Q2'25 trough of $774M, with TTM sales of $4.29B and sales Y/Y TTM +82.6%. Q1'26 operating income of $269M (23.0% op margin) and net income of $206M (17.6% net margin) mark a clean transition from the Q2'25 loss quarter, and gross margins are consistently in the 80%+ zone (Q1'26 81.9%). Balance sheet is adequate but not fortress-like: $1.71B cash vs. $1.27B debt, current ratio 3.13, working capital $2.87B — however debt/equity of 2.76x (headline figure of 276% in the fundamentals block) reflects a thin equity base ($1.08B), and ROE of 90%+ is flattered by that low denominator. Free cash flow is positive but lumpy ($49M in Q1'26 vs. $313M in Q3'25). Valuation is the friction point: trailing P/E ~75x, P/S 9.3x, EV/EBITDA 49x — priced for continued 40%+ EPS growth (fwd EPS $13.50 implies ~22x forward, more palatable but demanding). Capital allocation is skewing aggressive with the reported $2B Inceptive AI collaboration; that is the item most likely to pressure near-term FCF.
The 1h chart shows a violent sequence: a spike from ~$320 to $360 on July 9 (competitor trial failure), followed by a fast round-trip back to $281.83, then a bounce to the current $298 zone. The 4h chart confirms $278-282 as the key retest zone / short-term support, with resistance at the July 9 spike high ($330-360). Daily chart: still in a wider downtrend from the January $475+ high, price is -39.7% from 52-week high and only ~9% above 52-week low ($273.11) — the $273 level is the critical structural line; a break there invalidates the accumulation setup. Weekly forecast band actually points DOWN toward $228, which is a meaningful bearish tell from the longer-timeframe model, and its 1wk directional accuracy (50%) is below the naive baseline so I discount it, but the asymmetric downside call is worth respecting. SMA20/50 are essentially flat (+0.7%/+0.8%), SMA200 is -17.8% — stock is coiled just under longer-term resistance. RSI 48.7 is neutral. Model's 1d forecast is bullish (301.61) but the realized bounce is already stalling near that level.
The dominant signal is the July 9 failure of AstraZeneca/Ionis's Wainua Phase 3 ATTR-CM readout, which removed a key competitive threat to AMVUTTRA in a franchise that generates ~$4.4-4.7B of guided 2026 revenue. Multiple sell-side desks responded: Morgan Stanley raised PT to $400 (Equal-Weight), and social/wire chatter references Raymond James $468 and H.C. Wainwright $485 revisions — consensus target sits at $446 with a 1.67 recom (near strong-buy). This is a genuine fundamental positive, not just a sentiment blip. Offsetting: the stock is -24.9% YTD, -29.3% over the past 6 months, and the -4.5% intraday move despite the bullish backdrop suggests the good news is at least partially priced in already. Secondary items — expanded GENESIS Pharma European collaboration, Komodo/Inceptive AI partnerships, the 'Alnylam 2030' strategy — are supportive but not immediate catalysts. Broader market/crypto items in the feed are noise for this name.
- AMVUTTRA/ATTR-CM competitive whitespace expanded materially post July 9 Wainua Phase 3 failure — de-risks the $4.4-4.7B 2026 TTR revenue guide
- Q2 2026 earnings July 30 — consensus EPS $1.79; a beat + guide-raise is the near-term unlock
- Three ongoing Phase 3 trials (TRITON-CM, TRITON-PN, ZENITH) with enrollment milestones through 2H26
- GENESIS Pharma Northern European commercial expansion driving incremental TTR ex-US uptake
- $2B Inceptive Nucleics AI drug-discovery collaboration and expanded Komodo Health analytics deal supporting pipeline productivity
- 3-4 new IND filings planned by 2027 broadening pipeline optionality beyond TTR
- Valuation risk: 75x trailing P/E and 9.3x P/S leave no cushion for execution missteps
- Binary earnings event July 30 with history of large gaps in either direction
- $273 52-week low is critical; a daily close below breaks the multi-month structure
- Thin equity base ($1.08B) with $1.27B debt creates leverage sensitivity if FCF slows
- $2B Inceptive AI collaboration is a large capital commitment with uncertain near-term ROI
- Weekly forecast model points to $228 downside — a real bearish tail scenario to respect
- Competitive threat from CRISPR/gene-editing modalities in TTR long-term
- Retail sentiment is 100% bullish — contrarian caution warranted on positioning crowding
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord